FOLFOX4 plus cetuximab administered weekly or every two weeks in first-line treatment of patients with KRAS and NRAS wild-type (wt) metastatic colorectal cancer (mCRC).
Thomas Brodowicz
Honoraria - Amgen; Merck Serono
Damir Vrbanec
No relevant relationships to disclose
Klaus Kaczirek
Honoraria - Merck; Novartis; Roche
Research Funding - Covidien; Merck
Tudor-Eliade Ciuleanu
Consultant or Advisory Role - Amgen; Merck
Honoraria - Amgen; Merck
Regina Knittelfelder
No relevant relationships to disclose
Elisabeth Lindner
No relevant relationships to disclose
Diethelm Messinger
Employment or Leadership Position - IST GmbH
Christoph Zielinski
No relevant relationships to disclose
Berthold Streubel
No relevant relationships to disclose